[Federal Register Volume 69, Number 194 (Thursday, October 7, 2004)]
[Notices]
[Pages 60155-60156]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-22550]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-04-0588]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call 404-498-1210 or 
send comments to Seleda Perryman, CDC Assistant Reports Clearance 
Officer, 1600 Clifton Road, MS-E11, Atlanta, GA 30333 or send an e-mail 
to <a href="/cdn-cgi/l/email-protection#81eeece3c1e2e5e2afe6eef7"><span class="__cf_email__" data-cfemail="6d02000f2d0e090e430a021b">[email protected]</span></a>.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Written comments should be received 
within 60 days of this notice.

Proposed Project

    Evaluating the Impact of Lymphedema and a Lymphedema Management 
Intervention for Women with Lymphatic Filariasis: Understanding Issues 
Related to Quality of Life (OMB No. 0920-0588)--Extension--National 
Center for Infectious Diseases (NCID), Centers for Disease Control and 
Prevention (CDC).
    Lymphatic filariasis, a mosquito-transmitted parasitic disease 
affecting over 120 million people, is the second leading cause of 
permanent disability worldwide. Globally, lymphatic filariasis causes 
debilitating genital disease in an estimated 25 million men and 
lymphedema or elephantiasis of the leg in 15 million people, mostly 
women in poverty stricken countries. The World Health Organization 
(WHO) recently identified community management of chronic lymphedema as 
one of the top twenty lymphatic filariasis research priorities. Recent 
advances in the management of chronic lymphedema include a prescribed 
hygiene and wound care intervention. This intervention has shown 
promising results in: (1) Preventing bacterial infections thus reducing 
acute attacks; (2) anecdotally improving overall quality of life; (3) 
alleviating pain; (4) and preventing further suffering.
    The data gathered from this study will assist CDC in the 
development, monitoring and evaluation of morbidity control programs, 
and the provision of technical assistance to collaborating countries in 
the Global Alliance to Eliminate Lymphatic Filariasis. The data 
collected by this study will allow CDC to determine directly from 
affected women such information as knowledge and attitudes related to 
disease and secondary infections; perceptions of women related to 
disease transmission; health seeking practices; and current self-care 
of women who are not under care as well as those who are. This 
formative data will be used to assist the Ministry of Health in each 
country to develop new lymphedema management programs and modify 
current public health educational campaigns to recruit affected 
populations into treatment. The data will also provide the basis for 
culturally-tailored public health education strategies that increase 
the community's as well women's knowledge of lymphatic filariasis, 
address barriers to health care seeking, debunk myths surrounding 
disease and morbidity, utilize traditional health care practitioners, 
train community health care workers in management techniques, inform 
programs of the psychological, physical, and emotional needs that women 
have, and other issues identified in research findings.
    In addition, the data findings will also be used on a global level 
(in collaboration with WHO, PAHO, the Liverpool School of Medicine, 
Emory University, and others) to develop process and outcome indicators 
for evaluating and monitoring treatment programs at the clinic-level, 
community-level and home-level. As new programs are initiated, critical 
evaluation measures are needed to measure the effectiveness of these 
programs to avoid spending money on ineffective strategies. 
Operationally this data will allow us to develop a public health 
strategy for women with disease and their communities that include the 
regimen of meticulous local hygiene to the affected areas. It will also 
allow us to develop critical evaluation indicators to ensure 
appropriate program monitoring so that information will be immediately 
available for assessment by both the affected countries and the donor 
agencies supporting program activities. Data will be widely 
disseminated in reports, presentations, and professional peer-reviewed 
publications to persons who work in prevention of this disease. There 
is no cost to respondents.

                                             Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
                 Questionnaires                      Number of     responses per   per  response   Total burden
                                                    respondents     respondent       (in hrs.)         hours
----------------------------------------------------------------------------------------------------------------
Qualitative Interviews..........................              50               1           30/60              25
Quantitative Survey.............................             200               1               1             200
                                                 -----------------
    Total.......................................             250  ..............  ..............             225
----------------------------------------------------------------------------------------------------------------



[[Page 60156]]

Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 04-22550 Filed 10-6-04; 8:45 am]
BILLING CODE 4163-18-U


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>